C2 PHARMA
Helena Sáez Mingorance is a Senior Regulatory Affairs Associate at C2 PHARMA since July 2022, previously serving as a Regulatory Affairs Associate. Prior experience includes a position as a Regulatory Affairs Junior at Chemo from January to June 2022 and a master's internship at the Agencia Española de Medicamentos y Productos Sanitarios, focusing on the regulation of new therapies. Helena's educational background includes a Master’s Degree in Drug Research, Development, and Innovation from the University of Navarra, a study at the Università di Pavia, and a Bachelor of Pharmacy from Universidad de Granada.
This person is not in any offices
C2 PHARMA
C2 PHARMA (http://www.c2pharma.com) is a pharmaceutical group established in 2014. It manufactures and distributes active pharmaceutical ingredients (APls) and complex chemical compounds obtained from natural and synthetic origins. The current API product portfolio includes cyclopentolate, atropine, digoxin, homatropine, pilocarpine, brimonidine, latanoprost, bimatoprost and reaches more than 100 pharmaceutical companies across the United States, Western and Eastern Europe, South America, Asia, Middle-East and Africa. C² PHARMA also offers customized cold-chain logistics solutions through its specialized affiliate Logistics4Pharma (http://www.logistics4pharma.com) as well as R&D-scale synthesis services of complex organic molecules and impurities through its affiliate ASM Research Chemicals (http://www.asm-research-chemicals.de). C² PHARMA is a key sponsor of the “Partnership for a Better World” program that ensures a sustainable, traceable & fair-trade harvesting and sourcing of phytochemical and botanicals used for pharmaceutical APIs such as Pilocarpine. The program sustains of more than 1,000 families and contributes to the preservation of the Brazilian biodiversity. #c2Pharma; #C²Pharma; #c2 Pharma; #C² Pharma; #Centroflora CMS